Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries

• Status: Unknown status
• Trial end date: 2018-03-15
• Target enrollment: 0
• Participant gender: All

Summary

This study will be performed in Abo Elreesh Pediatric Hospital / Cairo University after obtaining approval by the University Ethics Committee, and a written informed consent from the parents or guardians.

Thirty six patients will be randomly assigned using an online randomization program (http://www.randomizer.org) and the sealed envelope method into three groups: Group D (n=12): Dexmetedomidine group. 0.5 ml of dexmetedomidine (2 μg/kg) added to bupivacaine, Group M (n=12) : Magnesium group.0.5 ml of magnesium sulphate (50 mg) added to bupivacaine, Group C (n=12) :Control group.bupivacaine 0.25% diluted in normal saline with total volume of 1 ml/kg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hagar hassanein refaee
• Collaborator: Cairo University
• Treatments: Bupivacaine; Magnesium Sulfate

Criteria

Inclusion Criteria:

• Age between 1 - 7 years old.

• American Society of Anesthesiologist (ASA) physical status class I- II.

• Patients scheduled for infra-umbilical orthopedic surgeries.

Exclusion Criteria:

• Patients with known allergy to the study drugs

• Suspected coagulopathy.

• Infection at the site of caudal block.

• History of developmental delay or neuromuscular disorders.

• Skeletal deformities.

• Patients on magnesium therapy